drugset / Trial / NCT01967875
A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether ERCC1(excision repair cross-complementation 1 ) expression has effects on platinum-based chemotherapy for patients with locally advanced or metastatic gastric cancer, and to explore if ERCC1 can act as a biological predictor for the individual therapy of gastric cancer
Timeline
- Start
- 2013-07
- Primary completion
- 2015-05
- Completion
- 2016-05
Outcome
Outcome not reported
Stopped (Enrollment): “slow enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Comparator | Capecitabine | Small molecule | 1700 mg/m2 | — |
| Comparator | Capecitabine | Small molecule | 2000 mg/m2 | — |